AU2022231584A1 - Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same - Google Patents

Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same Download PDF

Info

Publication number
AU2022231584A1
AU2022231584A1 AU2022231584A AU2022231584A AU2022231584A1 AU 2022231584 A1 AU2022231584 A1 AU 2022231584A1 AU 2022231584 A AU2022231584 A AU 2022231584A AU 2022231584 A AU2022231584 A AU 2022231584A AU 2022231584 A1 AU2022231584 A1 AU 2022231584A1
Authority
AU
Australia
Prior art keywords
fibroblast
pharmaceutical composition
cell
adm
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022231584A
Other languages
English (en)
Inventor
Takahiro IWAMIYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lymphogenix Ltd
Original Assignee
Lymphogenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lymphogenix Ltd filed Critical Lymphogenix Ltd
Publication of AU2022231584A1 publication Critical patent/AU2022231584A1/en
Assigned to LYMPHOGENIX LIMITED reassignment LYMPHOGENIX LIMITED Request for Assignment Assignors: METCELA INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022231584A 2021-03-04 2022-03-03 Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same Pending AU2022231584A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021-034016 2021-03-04
JP2021034018 2021-03-04
JP2021034016 2021-03-04
JP2021-034018 2021-03-04
PCT/JP2022/009205 WO2022186349A1 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
AU2022231584A1 true AU2022231584A1 (en) 2023-09-07

Family

ID=83155368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022231584A Pending AU2022231584A1 (en) 2021-03-04 2022-03-03 Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same

Country Status (8)

Country Link
US (1) US20240148795A1 (https=)
EP (1) EP4302771A4 (https=)
JP (2) JP7233147B2 (https=)
KR (1) KR20230154177A (https=)
AU (1) AU2022231584A1 (https=)
CA (1) CA3211113A1 (https=)
IL (1) IL305069A (https=)
WO (1) WO2022186349A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
JP2025515887A (ja) 2022-11-11 2025-05-20 エルジー エナジー ソリューション リミテッド 負極活物質、これを含む負極、これを含む二次電池、および負極活物質の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
EP3845635A4 (en) 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease

Also Published As

Publication number Publication date
WO2022186349A1 (ja) 2022-09-09
JP2023058660A (ja) 2023-04-25
EP4302771A1 (en) 2024-01-10
KR20230154177A (ko) 2023-11-07
IL305069A (en) 2023-10-01
US20240148795A1 (en) 2024-05-09
JP7233147B2 (ja) 2023-03-06
EP4302771A4 (en) 2025-04-02
CA3211113A1 (en) 2022-09-09
JPWO2022186349A1 (https=) 2022-09-09

Similar Documents

Publication Publication Date Title
Luo et al. Human bone marrow mesenchymal stem cell-derived extracellular vesicles inhibit shoulder stiffness via let-7a/Tgfbr1 axis
Chen et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair
Rieder et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis
Elmadbouh et al. Ex vivo delivered stromal cell-derived factor-1α promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium
Huang et al. Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs
Paddock et al. IL4Rα signaling promotes neonatal cardiac regeneration and cardiomyocyte cell cycle activity
JP7428389B2 (ja) 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団
JP2017530977A (ja) 肺高血圧症の治療剤としての心筋球由来細胞（ｃｄｃ）
AU2022231584A1 (en) Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
Jin et al. Angiogenic characteristics of human stromal vascular fraction in ischemic hindlimb
WO2023242605A1 (en) Extracellular vesicles for use in therapy
Song et al. Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway
US9950016B2 (en) Cell secreted proteins for the treatment of myocardial infarction
EP1693451A1 (en) Method of growing myocardial cells
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
KR20190015153A (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물
KR20190141234A (ko) 간엽계 줄기세포의 제조 방법, 간엽계 줄기세포의 치료 효과 마커, 치료 효과 판정 방법, 및 간엽계 줄기세포를 포함하는 세포 제제
Suzuki et al. The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment
Wang et al. Role of axonal guidance factor netrin-1 in human placental vascular growth
US20200011855A1 (en) COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS OR CIRRHOSIS, COMPRISING EXPRESSION OR ACTIVITY ENHANCER OF TIF1y AS ACTIVE INGREDIENT
Korchak et al. Endothelial nitric oxide synthase-engineered mesenchymal stromal cells induce anti-inflammation in experimental immune models
WO2006112390A1 (ja) 脂肪由来前駆細胞およびその利用
JP7193849B2 (ja) 虚血組織に集積するエクソソームおよびその製造方法
CN116322742A (zh) 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LYMPHOGENIX LIMITED

Free format text: FORMER APPLICANT(S): METCELA INC.